These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 22266797)

  • 1. Novel qualitative aspects of tissue fatty acids related to metabolic regulation: lessons from Elovl6 knockout.
    Shimano H
    Prog Lipid Res; 2012 Jul; 51(3):267-71. PubMed ID: 22266797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crucial role of a long-chain fatty acid elongase, Elovl6, in obesity-induced insulin resistance.
    Matsuzaka T; Shimano H; Yahagi N; Kato T; Atsumi A; Yamamoto T; Inoue N; Ishikawa M; Okada S; Ishigaki N; Iwasaki H; Iwasaki Y; Karasawa T; Kumadaki S; Matsui T; Sekiya M; Ohashi K; Hasty AH; Nakagawa Y; Takahashi A; Suzuki H; Yatoh S; Sone H; Toyoshima H; Osuga J; Yamada N
    Nat Med; 2007 Oct; 13(10):1193-202. PubMed ID: 17906635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5,5-Dimethyl-3-(5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)-1-phenyl-3-(trifluoromethyl)-3,5,6,7-tetrahydro-1H-indole-2,4-dione, a potent inhibitor for mammalian elongase of long-chain fatty acids family 6: examination of its potential utility as a pharmacological tool.
    Shimamura K; Kitazawa H; Miyamoto Y; Kanesaka M; Nagumo A; Yoshimoto R; Aragane K; Morita N; Ohe T; Takahashi T; Nagase T; Sato N; Tokita S
    J Pharmacol Exp Ther; 2009 Jul; 330(1):249-56. PubMed ID: 19359527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and characterization of a novel potent, selective and orally active inhibitor for mammalian ELOVL6.
    Shimamura K; Nagumo A; Miyamoto Y; Kitazawa H; Kanesaka M; Yoshimoto R; Aragane K; Morita N; Ohe T; Takahashi T; Nagase T; Sato N; Tokita S
    Eur J Pharmacol; 2010 Mar; 630(1-3):34-41. PubMed ID: 20045404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cideb regulates diet-induced obesity, liver steatosis, and insulin sensitivity by controlling lipogenesis and fatty acid oxidation.
    Li JZ; Ye J; Xue B; Qi J; Zhang J; Zhou Z; Li Q; Wen Z; Li P
    Diabetes; 2007 Oct; 56(10):2523-32. PubMed ID: 17646209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elovl6 promotes nonalcoholic steatohepatitis.
    Matsuzaka T; Atsumi A; Matsumori R; Nie T; Shinozaki H; Suzuki-Kemuriyama N; Kuba M; Nakagawa Y; Ishii K; Shimada M; Kobayashi K; Yatoh S; Takahashi A; Takekoshi K; Sone H; Yahagi N; Suzuki H; Murata S; Nakamuta M; Yamada N; Shimano H
    Hepatology; 2012 Dec; 56(6):2199-208. PubMed ID: 22753171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrophage Elovl6 deficiency ameliorates foam cell formation and reduces atherosclerosis in low-density lipoprotein receptor-deficient mice.
    Saito R; Matsuzaka T; Karasawa T; Sekiya M; Okada N; Igarashi M; Matsumori R; Ishii K; Nakagawa Y; Iwasaki H; Kobayashi K; Yatoh S; Takahashi A; Sone H; Suzuki H; Yahagi N; Yamada N; Shimano H
    Arterioscler Thromb Vasc Biol; 2011 Sep; 31(9):1973-9. PubMed ID: 21817094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [SREBP-1c and Elovl6 as Targets for Obesity-related Disorders].
    Shimano H
    Yakugaku Zasshi; 2015; 135(9):1003-9. PubMed ID: 26329544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elovl6: a new player in fatty acid metabolism and insulin sensitivity.
    Matsuzaka T; Shimano H
    J Mol Med (Berl); 2009 Apr; 87(4):379-84. PubMed ID: 19259639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deletion of ELOVL6 blocks the synthesis of oleic acid but does not prevent the development of fatty liver or insulin resistance.
    Moon YA; Ochoa CR; Mitsche MA; Hammer RE; Horton JD
    J Lipid Res; 2014 Dec; 55(12):2597-605. PubMed ID: 25281760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deranged fatty acid composition causes pulmonary fibrosis in Elovl6-deficient mice.
    Sunaga H; Matsui H; Ueno M; Maeno T; Iso T; Syamsunarno MR; Anjo S; Matsuzaka T; Shimano H; Yokoyama T; Kurabayashi M
    Nat Commun; 2013; 4():2563. PubMed ID: 24113622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ursodeoxycholic acid improves insulin sensitivity and hepatic steatosis by inducing the excretion of hepatic lipids in high-fat diet-fed KK-Ay mice.
    Tsuchida T; Shiraishi M; Ohta T; Sakai K; Ishii S
    Metabolism; 2012 Jul; 61(7):944-53. PubMed ID: 22154323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice.
    Dentin R; Benhamed F; Hainault I; Fauveau V; Foufelle F; Dyck JR; Girard J; Postic C
    Diabetes; 2006 Aug; 55(8):2159-70. PubMed ID: 16873678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Role of Fatty Acid Elongase Elovl6 in the Regulation of Fatty Acid Quality and Lifestyle-related Diseases].
    Matsuzaka T; Shimano H
    Yakugaku Zasshi; 2022; 142(5):473-476. PubMed ID: 35491151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absence of Elovl6 attenuates steatohepatitis but promotes gallstone formation in a lithogenic diet-fed Ldlr(-/-) mouse model.
    Kuba M; Matsuzaka T; Matsumori R; Saito R; Kaga N; Taka H; Ikehata K; Okada N; Kikuchi T; Ohno H; Han SI; Takeuchi Y; Kobayashi K; Iwasaki H; Yatoh S; Suzuki H; Sone H; Yahagi N; Arakawa Y; Fujimura T; Nakagawa Y; Yamada N; Shimano H
    Sci Rep; 2015 Dec; 5():17604. PubMed ID: 26619823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ablation of the very-long-chain fatty acid elongase ELOVL3 in mice leads to constrained lipid storage and resistance to diet-induced obesity.
    Zadravec D; Brolinson A; Fisher RM; Carneheim C; Csikasz RI; Bertrand-Michel J; Borén J; Guillou H; Rudling M; Jacobsson A
    FASEB J; 2010 Nov; 24(11):4366-77. PubMed ID: 20605947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effects of n-3 polyunsaturated fatty acids on metabolic control and vascular reactivity in the type 2 diabetic ob/ob mouse.
    Mustad VA; Demichele S; Huang YS; Mika A; Lubbers N; Berthiaume N; Polakowski J; Zinker B
    Metabolism; 2006 Oct; 55(10):1365-74. PubMed ID: 16979408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Partial leptin deficiency favors diet-induced obesity and related metabolic disorders in mice.
    Begriche K; Lettéron P; Abbey-Toby A; Vadrot N; Robin MA; Bado A; Pessayre D; Fromenty B
    Am J Physiol Endocrinol Metab; 2008 May; 294(5):E939-51. PubMed ID: 18349116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deficiency of carbohydrate-activated transcription factor ChREBP prevents obesity and improves plasma glucose control in leptin-deficient (ob/ob) mice.
    Iizuka K; Miller B; Uyeda K
    Am J Physiol Endocrinol Metab; 2006 Aug; 291(2):E358-64. PubMed ID: 16705063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocyte ELOVL Fatty Acid Elongase 6 Determines Ceramide Acyl-Chain Length and Hepatic Insulin Sensitivity in Mice.
    Matsuzaka T; Kuba M; Koyasu S; Yamamoto Y; Motomura K; Arulmozhiraja S; Ohno H; Sharma R; Shimura T; Okajima Y; Han SI; Aita Y; Mizunoe Y; Osaki Y; Iwasaki H; Yatoh S; Suzuki H; Sone H; Takeuchi Y; Yahagi N; Miyamoto T; Sekiya M; Nakagawa Y; Ema M; Takahashi S; Tokiwa H; Shimano H
    Hepatology; 2020 May; 71(5):1609-1625. PubMed ID: 31529722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.